Structure via PubChem · Public domain (PubChem)
revefenacin
Sign in to saveAlso known as TD-4208
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.
Key facts
- Drug.image
- Revefenacin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Yupelri
- Drug.MedlinePlus
- a619009
- Drug.DailyMedID
- Revefenacin
- Drug.routes_of_administration
- Inhalation
- Drug.ATC_prefix
- R03
- Drug.ATC_suffix
- BB08
- Drug.legal_US
- Rx-only
- Drug.CAS_number
- 864750-70-9
- Drug.PubChem
- 11753673
- Drug.DrugBank
- DB11855
- Drug.ChemSpiderID
- 9928376
- Drug.UNII
- G2AE2VE07O
- Drug.KEGG
- D10978
- Drug.C
- 35
- Drug.H
- 43
via Wikipedia infobox
Chemical data
- Formula
- C35H43N5O4
- Molecular weight
- 597.7 g/mol
- IUPAC name
- [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate
- SMILES
- CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
- InChIKey
- FYDWDCIFZSGNBU-UHFFFAOYSA-N
- XLogP
- 4.1
- Polar surface area
- 108 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2018
- Admin. routes
- topical
- Indications
- chronic obstructive pulmonary disease, liver disease, kidney disease, Airway obstruction
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 597.332
- Has use
- medication
Show 2 more facts
- canonical SMILES
- CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
- chemical formula
- C₃₅H₄₃N₅O₄
via Wikidata · CC0
~1 min read
Encyclopedic overview
4 sectionsContents
- Society and culture
- Brand names
- Synthesis
- References
Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.
Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.
Excerpted from Wikipedia’s “revefenacin” article, available under the CC BY-SA 4.0 licence.